Met-independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Tate, Amanda ^a   Isotani, Shuji ^a   Bradley, Michael J ^b   Sikes, Robert A ^b   Davis, Rodney ^c   Chung, Leland W K ^a   Edlund, Magnus ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; LAMININ; NUCLEOLIN; NUCLEOLIN ANTIBODY; PROTEIN ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL STIMULATION; CELL STRAIN LNCAP; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CELL ADHESION; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED;

EID: 33748337715     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-197     Document Type: Article

References (119)

1. Chung LW, Hsieh CL, Law A, Sung SY, Gardner TA, Egawa M, Matsubara S, Zhau HE: New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology 2003, 62(5 Suppl 1):44-54.
2. Tuxhorn JA, Ayala GE, Rowley DR: Reactive stroma in prostate cancer progression. J Urol 2001, 166(6):2472-2483.
3. McCawley LJ, Matrisian LM: Tumor progression: defining the soil round the tumor seed. Curr Biol 2001, 11(1):R25-27.
4. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001, 411(6835):375-379.
5. David Roodman G: Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 2003, 97(3 Suppl):733-738.
6. Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005, 173(1):10-20.
7. Nemeth JA, Lee C: Prostatic ductal system in rats: regional variation in stromal organization. Prostate 1996, 28(2):124-128.
8. Cunha GR, Battle E, Young P, Brody J, Donjacour A, Hayashi N, Kinbara H: Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epithelial Cell Biol 1992, 1(2):76-83.
9. Edlund M, Sung SY, Chung LW: Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem 2004, 91(4):686-705.
10. Sung SY, Chung LW: Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002, 70(9-10):506-521.
11. Liotta LA, Rao CN: Tumor invasion and metastasis. Monogr Pathol 1986:183-192.
12. Ma H, Calderon TM, Kessel T, Ashton AW, Berman JW: Mechanisms of hepatocyte growth factor-mediated vascular smooth muscle cell migration. Circ Res 2003, 93(11):1066-1073.
13. Santos OF, Moura LA, Rosen EM, Nigam SK: Modulation of HGF-induced tubulogenesis and branching by multiple phosphorylation mechanisms. Dev Biol (N Y 1985) 1993, 159(2):535-548.
14. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4(12):915-925.
15. Andermarcher E, Surani MA, Gherardi E: Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev Genet 1996, 18(3):254-266.
16. Weidner KM, Sachs M, Birchmeier W: The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993, 121(1):145-154.
17. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G: Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A 1987, 84(18):6379-6383.
18. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311(5981):29-33.
19. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251(4995):802-804.
20. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK: Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO Journal 1991, 10(10):2867-2878.
21. Knudsen BS, Edlund M: Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004, 91:31-67.
22. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT: Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994, 269(15):11216-11223.
23. Hartmann G, Prospero T, Brinkmann V, Ozcelik C, Winter G, Hepple J, Batley S, Bladt F, Sachs M, Birchmeier C, et al.: Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr Biol 1998, 8(3):125-134.
24. Lamszus K, Joseph A, Jin L, Yao Y, Chowdhury S, Fuchs A, Polverini PJ, Goldberg ID, Rosen EM: Scatter factor binds to thrombospondin and other extracellular matrix components. Am J Pathol 1996, 149(3):805-819.
25. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W: Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990, 111 (5 Pt 1):2097-2108.
26. Rosen EM, Goldberg ID, Kacinski BM, Buckholz T, Vinter DW: Smooth muscle releases an epithelial cell scatter factor which binds to heparin. In Vitro Cell Dev Biol 1989, 25(2):163-173.
27. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF, Knudsen BS: Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 2001, 159(2):579-590.
28. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147(2):386-396.
29. Pisters LL, Troncoso P. Zhau HE, Li W, von Eschenbach AC, Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995, 154(1):293-298.
30. Xue Y, Smedts F, Ruijter ET, Debruyne FM, de la Rosette JJ, Schalken JA: Branching activity in the human prostate: a closer look at the structure of small glandular buds. Eur Urol 2001, 39(2):222-231.
31. Xue Y, Sonke G, Schoots C, Schalken J, Verhofstad A, de la Rosette J, Smedts F: Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. Prostate 2001, 49(2):132-139.
32. Rosen EM, Nigam SK, Goldberg ID: Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994, 127(6 Pt 2):1783-1787.
33. Rosario M, Birchmeier W: How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003, 13(6):328-335.
34. Birchmeier C, Gherardi E: Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998, 8(10):404-410.
35. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W: Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995, 131(6 Pt 1): 1573-1586.
36. McNeal JE: Morphogenesis of prostatic carcinoma. Cancer 1965, 18(12):1659-1666.
37. Bonkhoff H: Morphogenesis of prostate cancer. Eur Urol 2001, 39(Suppl 4):5-7.
38. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19(43):4947-4953.
39. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina. G, Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19(12):1547-1555.
40. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, et al.: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18(14):2343-2350.
41. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997, 94(21):11445-11450.
42. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, et al.: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005, 113(4):678-682.
43. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF: High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002, 60(6):1113-1117.
44. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF: The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 1998, 95(24):14417-14422.
45. Jeffers M, Rong S, Woude GF: Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996, 74(9):505-513.
46. Watanabe M, Fukutome K, Kato H, Murata M, Kawamura J, Shiraishi T, Yatani R: Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 1999, 141(1-2):173-178.
47. Kurimoto S, Moriyama N, Horie S, Sakai M, Kameyama S, Akimoto Y, Hirano H, Kawabe K: Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998, 30(1):27-32.
48. Tsuka H, Mori H, Li B, Kanamaru H, Matsukawa S, Okada K: Enhanced hepatocyte growth factor level in human prostate cancer treated with endocrine therapy. Int J Oncol 1998, 13(1):169-176.
49. Tsuka H, Mori H, Li B, Kanamaru H, Matsukawa S, Okada K: Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues. Int J Oncol 1998, 13(5):927-934.
50. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, Saiki I: Expression of membrane-type 1 matrix metalloproteinase (MTI-MMP) on prostate cancer cell lines. Cancer Lett 2000, 155(2):173-179.
51. Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA: Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines. Endocrinology 2000, 141(7):2567-2573.
52. Nishimura T, Toda S, Mitsumoto T, Oono S, Sugihara H: Effects of hepatocyte growth factor, transforming growth factor-beta 1 and epidermal growth factor on bovine corneal epithelial cells under epithelial-keratocyte interaction in reconstruction culture. Exp Eye Res 1998, 66(1):105-116.
53. Nishimura K, Kitamura M, Miura H, Nonomura N, Takada S, Takahara S, Matsumoto K, Nakamura T, Matsumiya K: Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate 1999, 41(3):145-153.
54. Nishimura K, Matsumiya K, Miura H, Tsujimura A, Nonomura N, Matsumoto K, Nakamura T, Okuyama A: Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells. Int J Androl 2003, 26(3):175-179.
55. Nishimura K, Kitamura M, Takada S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K, Okuyama A: Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 1998, 5(3):276-281.
56. Chan AM, Rubin JS, Bottaro DP, Hirschfield DW, Chedid M, Aaronson SA: Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991, 254(5036):1382-1385.
57. Chan A, Rubin J, Bottaro D, Hirschfield D, Chedid M, Aaronson SA: Isoforms of human HGF and their biological activities. EXS 1993, 65:67-79.
58. Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM: Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 1991, 266(29):19558-19564.
59. Gandino L, Longati P, Medico E, Prat M, Comoglio PM: Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem 1994, 269(3):1815-1820.
60. Prat M, Crepaldi T, Gandino L, Giordano S, Longati P, Comoglio P: C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 1991, 11(12):5954-5962.
61. Rodrigues GA, Naujokas MA, Park M: Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 1991, 11(6):2962-2970.
62. Rodrigues GA, Park M: Isoforms of the met receptor tyrosine kinase. EXS 1993, 65:167-179.
63. Wordinger RJ, Clark AF, Agarwal R, Lambert W, Wilson SE: Expression of alternatively spliced growth factor receptor isoforms in the human trabecular meshwork. Invest Ophthalmol Vis Sci 1999, 40(1):242-247.
64. Meiners S, Brinkmann V, Naundorf H, Birchmeier W: Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene 1998, 16(1):9-20.
65. Birchmeier W, Brinkmann V, Niemann C, Meiners S, DiCesare S, Naundorf H, Sachs M: Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp 1997, 212:230-240.
66. Kim SJ, Shiba E, Tsukamoto F, Izukura M, Taguchi T, Yoneda K, Tanji Y, Kimoto Y, Takai SI: The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer. Oncol Rep 1998, 5(2):431-435.
67. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S: Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342(6248):440-443.
68. Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HE, Chung LW: Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001, 12(2):99-107.
69. Ginisty H, Sicard H, Roger B, Bouvet P: Structure and functions of nucleolin. J Cell Sci 1999, 112(Pt 6):761-772.
70. Srivastava M, Pollard HB: Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999, 13(14):1911-1922.
71. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, McCormick LM, Bu G, Kadomatsu K: Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002, 22(19):6788-6796.
72. Joo EJ, ten Dam GB, van Kuppevelt TH, Toida T, Linhardt RJ, Kim YS: Nucleolin: acharan sulfate-binding protein on the surface of cancer cells. Glycobiology 2005, 15(1):1-9.
73. Callebaut C, Nisole S, Briand JP, Krust B, Hovanessian AG: Inhibition of HIV infection by the cytokine midkine. Virology 2001, 281(2):248-264.
74. Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG: The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem 2002, 277(40):37492-37502.
75. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163(4):871-878.
76. Legrand D, Vigie K, Said EA, Elass E, Masson M, Slomianny MC, Carpentier M, Briand JP, Mazurier J, Hovanessian AG: Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 2004, 271(2):303-317.
77. Laber DA, Choudry MA, Taft BS, Bhupalam L, Sharma VR, Hendler FJ, Barnhart KM: A phase 1 study of AGRO100 in advanced cancer. Journal of Clinical Oncology 2004, 22(14S):3112.
78. Barnhart KM, Laber DA, Bates PJ, Trent JO, Miller DM: AGRO100: The translation from lab to clinic of a tumor-targeted nucleic acid aptamer. Journal of Clinical Oncology 2004, 22(14S):3126.
79. Ozen M, Multani AS, Chang S-M, Von Eschenbach AC, Chung LWK, Pathak S: Establishment of an in vitro cell model system to study human prostate carcinogenesis: involvement of chromosome 5 in early stages of neoplastic transformation. Internation Journal of Oncology 1996, 8:883-888.
80. Kleinman HK, McGarvey ML, Hassell JR, Martin GR: Formation of a supramolecular complex is involved in the reconstitution of basement membrane components. Biochemistry 1983, 22(21):4969-4974.
81. Davis LA, Ogle RC, Little CD: Embryonic heart mesenchymal cell migration in laminin. Dev Biol (N Y 1985) 1989, 133(1):37-43.
82. Vafa A, Zhang Y, Sikes RA, Marengo SR: Overexpression of p185erbB2/neu in the NbE prostatic epithelial cell line increases cellular spreading and the expression of integrin alpha6betal. Int J Oncol 1998, 13(6):1191-1197.
83. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987, 47(4):943-946.
84. Romijn JC, Verkoelen CF, Schroeder FH: Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988, 12(1):99-110.
85. Smart EJ, Ying YS, Mineo C, Anderson RG: A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci U S A 1995, 92(22):10104-10108.
86. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994, 57(3):406-412.
87. Yamada KM, Even-Ram S: Integrin regulation of growth factor receptors. Nat Cell Biol 2002, 4(4):E75-76.
88. You X, Yu HM, Cohen-Gould L, Cao B, Symons M, Vande Woude GF, Knudsen BS: Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Exp Cell Res 2003, 288(2):246-256.
89. Comoglio PM: Pathway specificity for Met signalling. Nat Cell Biol 2001, 3(7):E161-162.
90. Zarnegar R, DeFrances MC, Oliver L, Michalopoulos G: Identification and partial characterization of receptor binding sites for HGF on rat hepatocytes. Biochem Biophys Res Commun 1990, 173(3):1179-1185.
91. Wielenga VJ, van der Voort R, Taher TE, Smit L, Beuling EA, van Krimpen C, Spaargaren M, Pals ST: Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am J Pathol 2000, 157(5):1563-1573.
92. van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 1999, 274(10):6499-6506.
93. Pollack AL, Apodaca G, Mostov KE: Hepatocyte growth factor induces MDCK cell morphogenesis without causing loss of tight junction functional integrity. Am J Physiol Cell Physiol 2004, 286(3):C482-494.
94. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST: Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99(4):1405-1410.
95. Matsumoto K, Nakamura T: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001, 59(6):2023-2038.
96. Orrick LR, Olson MO, Busch H: Comparison of nucleolar proteins of normal rat liver and Novikoff hepatoma ascites cells by two-dimensional polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 1973, 70(5):1316-1320.
97. Derenzini M, Sirri V, Trere D, Ochs RL: The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest 1995, 73(4):497-502.
98. Tawfic S, Goueli SA, Olson MO, Ahmed K: Androgenic regulation of phosphorylation and stability of nucleolar protein nucleolin in rat ventral prostate. Prostate 1994, 24(2):101-106.
99. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, McLeod DG, Moul JW, Srivastava S: Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 2001, 92(3):322-328.
100. Mi Y, Thomas SD, Xu X, Casson LK, Miller DM, Bates PJ: Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. J Biol Chem 2003, 278(10):8572-8579.
101. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM: Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol Chem 1999, 274(37):26369-26377.
102. Sikes RA, Cooper CR, Beck GL, Pruitt F, Brown ML, Balian G: Bone stromall cells as therapeutics targets in osseous metastasis. Volume 15. Kluwer Academic Publishers, Boston MA; 2005.
103. Bugler B, Caizergues-Ferrer M, Bouche G, Bourbon H, Amalric F: Detection and localization of a class of proteins immunologically related to a 100-kDa nucleolar protein. Eur J Biochem 1982, 128(2-3):475-480.
104. Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, Krust B: The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 2000, 261(2):312-328.
105. Pfeifle J, Anderer FA: Isolation and characterization of phosphoprotein pp 105 from simian virus 40-transformed mouse fibroblasts. Biochim Biophys Acto 1983, 762(1):86-93.
106. Pfeifle J, Hagmann W, Anderer FA: Cell adhesion-dependent differences in endogenous protein phosphorylation on the surface of various cell lines. Biochim Biophys Acta 1981, 670(2):274-284.
107. Borer RA, Lehner CF, Eppenberger HM, Nigg EA: Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989, 56(3):379-390.
108. Larrucea S, Gonzalez-Rubio C, Cambronero R, Ballou B, Bonay P, Lopez-Granados E, Bouvet P, Fontan G, Fresno M, Lopez-Trascasa M: Cellular adhesion mediated by factor J, a complement inhibitor. Evidence for nucleolin involvement. J Biol Chem 1998, 273(48):31718-31725.
109. Becker J, Craig EA: Heat-shock proteins as molecular chaperones. Eur J, Biochem 1994, 219(1-2):11-23.
110. Lee CH, Chang SC, Chen CJ, Chang MF: The nucleolin binding activity of hepatitis delta antigen is associated with nucleolus targeting. J Biol Chem 1998, 273(13):7650-7656.
111. Take M, Tsutsui J, Obama H, Ozawa M. Nakayama T, Maruyama I, Arima T, Muramatsu T: Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem (Tokyo) 1994, 116(5):1063-1068.
112. Kleinman HK, Weeks BS, Cannon FB, Sweeney TM, Sephel GC, Clement B, Zain M, Olson MO, Jucker M, Burrous BA: Identification of a 110-kDa nonintegrin cell surface laminin-binding protein which recognizes an A chain neurite-promoting peptide. Arch Biochem Biophys 1991, 290(2):320-325.
113. Kibbey MC, Johnson B, Petryshyn R, Jucker M, Kleinman HK: A 110-kD nuclear shuttling protein, nucleolin, binds to the neurite-promoting IKVAV site of laminin-1. J Neurosci Res 1995, 42(3):314-322.
114. Yu D, Schwartz MZ, Petryshyn R: Effect of laminin on the nuclear localization of nucleolin in rat intestinal epithelial IEC-6 cells. Biochem Biophys Res Commun 1998, 247(1):186-192.
115. Lozano E, Betson M, Braga VM: Tumor progression: Small GTPases and loss of cell-cell adhesion. Bioessays 2003, 25(5):452-463.
116. Titus B, Schwartz MA, Theodorescu D: Rho proteins in cell migration and metastasis. Crit Rev Eukaryot Gene Expr 2005, 15(2):103-114.
117. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC: Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 2005, 27(6):602-613.
118. Schwartz M: Rho signalling at a glance. J Cell Sci 2004, 117(Pt 23):5457-5458.
119. Ridley AJ: Intracellular regulation. Rac and Bcr regulate phagocytic phoxes. Curr Biol 1995, 5(7):710-712.